CXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives.

Xinxin Huang,Juncheng Hao,Yan Qin Tan,Tao Zhu,Vijay Pandey,Peter E. Lobie
DOI: https://doi.org/10.3390/ijms23052642
IF: 5.6
2022-01-01
International Journal of Molecular Sciences
Abstract:Patients with epithelial ovarian cancer (EOC) are often diagnosed at an advanced stage due to nonspecific symptoms and ineffective screening approaches. Although chemotherapy has been available and widely used for the treatment of advanced EOC, the overall prognosis remains dismal. As part of the intrinsic defense mechanisms against cancer development and progression, immune cells are recruited into the tumor microenvironment (TME), and this process is directed by the interactions between different chemokines and their receptors. In this review, the functional significance of CXC chemokine ligands/chemokine receptors (CXCL/CXCR) and their roles in modulating EOC progression are summarized. The status and prospects of CXCR/CXCL-based theranostic strategies in EOC management are also discussed.
What problem does this paper attempt to address?